Adaptimmune Therapeutics (ADAP) Stock Rating Lowered by ValuEngine

Adaptimmune Therapeutics (NASDAQ:ADAP) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

Other analysts have also recently issued research reports about the stock. Raymond James cut their price target on shares of Adaptimmune Therapeutics from $20.00 to $16.00 and set a “buy” rating on the stock in a report on Monday, October 22nd. Zacks Investment Research upgraded shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 7th. Cowen reiterated a “buy” rating on shares of Adaptimmune Therapeutics in a report on Thursday, August 2nd. BidaskClub raised Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, September 29th. Finally, TheStreet lowered Adaptimmune Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, July 16th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $15.44.

NASDAQ:ADAP opened at $6.65 on Tuesday. The firm has a market capitalization of $616.54 million, a P/E ratio of -8.31 and a beta of 2.02. Adaptimmune Therapeutics has a twelve month low of $5.73 and a twelve month high of $14.63.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.09. The business had revenue of $40.79 million for the quarter, compared to analysts’ expectations of $29.41 million. Adaptimmune Therapeutics had a negative net margin of 139.57% and a negative return on equity of 46.63%. On average, equities analysts expect that Adaptimmune Therapeutics will post -1.01 EPS for the current year.

In other news, major shareholder Enterprise Associates 14 New acquired 3,000,000 shares of the stock in a transaction on Friday, September 7th. The stock was acquired at an average price of $1.67 per share, with a total value of $5,010,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ali Behbahani acquired 12,000,000 shares of the stock in a transaction on Friday, September 7th. The shares were purchased at an average cost of $1.67 per share, with a total value of $20,040,000.00. The disclosure for this purchase can be found here. Company insiders own 26.47% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Arbitrage SA purchased a new position in shares of Adaptimmune Therapeutics in the 2nd quarter worth about $122,000. BB&T Securities LLC purchased a new position in shares of Adaptimmune Therapeutics in the 2nd quarter worth about $128,000. Jane Street Group LLC purchased a new position in shares of Adaptimmune Therapeutics in the 1st quarter worth about $168,000. Trexquant Investment LP purchased a new position in shares of Adaptimmune Therapeutics in the 2nd quarter worth about $178,000. Finally, Trellus Management Company LLC purchased a new position in shares of Adaptimmune Therapeutics in the 2nd quarter worth about $195,000. 58.99% of the stock is owned by hedge funds and other institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

Further Reading: Should I invest in “strong buy” stocks?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply